NASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis $247.61 +4.29 (+1.76%) (As of 07/2/2024 ET) Add Compare Share Share Today's Range$242.08▼$250.0650-Day Range$143.31▼$247.6152-Week Range$141.98▼$252.87Volume1.58 million shsAverage Volume888,290 shsMarket Capitalization$31.32 billionP/E RatioN/ADividend YieldN/APrice Target$246.41 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Alnylam Pharmaceuticals alerts: Email Address Alnylam Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside0.5% Downside$246.41 Price TargetShort InterestHealthy1.68% of Shares Sold ShortDividend StrengthN/ASustainability-1.52Upright™ Environmental ScoreNews Sentiment0.51Based on 45 Articles This WeekInsider TradingSelling Shares$13.44 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.92) to ($2.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.09 out of 5 starsMedical Sector170th out of 914 stocksPharmaceutical Preparations Industry65th out of 433 stocks 2.3 Analyst's Opinion Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 16 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alnylam Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.68% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently decreased by 14.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlnylam Pharmaceuticals has received a 63.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Gene therapy medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alnylam Pharmaceuticals is -1.52. Previous Next 3.1 News and Social Media Coverage News SentimentAlnylam Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 45 news articles for Alnylam Pharmaceuticals this week, compared to 9 articles on an average week.Search Interest22 people have searched for ALNY on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.MarketBeat Follows10 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,436,711.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alnylam Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($3.92) to ($2.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -92.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -92.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Alnylam Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Digital Mavericks Media1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.Click here to check it out. About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Read More ALNY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALNY Stock News HeadlinesJune 27, 2024 | insidertrades.comInsider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Sells 1,198 Shares of StockJune 27, 2024 | insidertrades.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CFO Jeffrey V. Poulton Sells 1,605 SharesJuly 3, 2024 | Digital Mavericks Media (Ad)1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.July 2 at 1:40 AM | americanbankingnews.comQ1 2025 Earnings Estimate for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Issued By Zacks ResearchJuly 1 at 9:22 AM | americanbankingnews.comAlnylam Pharmaceuticals' (ALNY) Neutral Rating Reiterated at Cantor FitzgeraldJuly 1 at 4:36 AM | americanbankingnews.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest UpdateJune 30 at 2:50 AM | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $288.00June 29, 2024 | americanbankingnews.comLeerink Partnrs Analysts Increase Earnings Estimates for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)July 3, 2024 | Digital Mavericks Media (Ad)1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.June 28, 2024 | americanbankingnews.comJeffrey V. Poulton Sells 1,605 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) StockJune 28, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Increased to $295.00 by Analysts at Stifel NicolausJune 28, 2024 | americanbankingnews.comKevin Joseph Fitzgerald Sells 1,198 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) StockJune 27, 2024 | americanbankingnews.comPushkal Garg Sells 2,103 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) StockJune 27, 2024 | americanbankingnews.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director David E. I. Pyott Sells 32,450 Shares of StockJune 27, 2024 | americanbankingnews.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet Sells 8,301 Shares of StockJune 27, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $291.00 at CitigroupJune 27, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $291.00June 27, 2024 | americanbankingnews.comBank of America Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $295.00June 27, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Given New $282.00 Price Target at TD CowenJune 27, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $159.00June 26, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Reaches New 12-Month High on Analyst UpgradeJune 26, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $260.00 at Evercore ISIJune 26, 2024 | americanbankingnews.comRoyal Bank of Canada Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $250.00June 26, 2024 | americanbankingnews.comBMO Capital Markets Reiterates "Outperform" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)June 26, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Sees Strong Trading Volume After Analyst UpgradeJune 25, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $207.00 at Wells Fargo & CompanyJune 25, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $250.00See More Headlines Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/02/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALNY CUSIP02043Q10 CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$246.41 High Stock Price Target$400.00 Low Stock Price Target$150.00 Potential Upside/Downside-0.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage24 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-440,240,000.00 Net Margins-16.58% Pretax Margin-16.21% Return on EquityN/A Return on Assets-8.92% Debt Debt-to-Equity RatioN/A Current Ratio3.17 Quick Ratio3.07 Sales & Book Value Annual Sales$1.83 billion Price / Sales17.13 Cash FlowN/A Price / Cash FlowN/A Book Value($1.76) per share Price / Book-140.69Miscellaneous Outstanding Shares126,490,000Free Float124,595,000Market Cap$31.32 billion OptionableOptionable Beta0.37 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Yvonne L. Greenstreet M.B.A. (Age 61)MBChB, CEO & Director Comp: $2.15MMr. Jeffrey V. Poulton M.B.A. (Age 56)CFO & Executive VP Comp: $1.05MDr. Akshay K. Vaishnaw M.D. (Age 61)Ph.D., Chief Innovation Officer & Member of the Scientific Advisory Board Comp: $1.12MDr. Pushkal P. Garg M.D. (Age 56)Chief Medical Officer and Executive VP of Development & Medical Affairs Comp: $1.06MMr. Tolga Tanguler M.B.A. (Age 51)Executive VP & Chief Commercial Officer Comp: $971.3kMr. Timothy J. MainesChief Technical Operations & Quality OfficerDr. Kevin Joseph Fitzgerald Ph.D. (Age 55)Senior VP, Head of Research & Chief Scientific Officer Ms. Christine Regan Lindenboom (Age 43)Senior VP of Investor Relations & Corporate Communications Mr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerMr. Evan Lippman M.B.A.Chief Corporate Development & Strategy OfficerMore ExecutivesKey CompetitorsHorizon Therapeutics PublicNASDAQ:HZNPRoyalty PharmaNASDAQ:RPRXBeiGeneNASDAQ:BGNESarepta TherapeuticsNASDAQ:SRPTMyoKardiaNASDAQ:MYOKView All CompetitorsInsiders & InstitutionsGAMMA Investing LLCBought 205 shares on 7/2/2024Ownership: 0.000%Yvonne GreenstreetSold 8,301 sharesTotal: $1.92 M ($230.99/share)Jeffrey V PoultonSold 1,605 sharesTotal: $370,755.00 ($231.00/share)Pushkal GargSold 2,103 sharesTotal: $485,771.97 ($230.99/share)Kevin Joseph FitzgeraldSold 1,198 sharesTotal: $276,726.02 ($230.99/share)View All Insider TransactionsView All Institutional Transactions Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.: Alnylam Pharmaceuticals has received positive ratings from multiple equity research analysts, with an average target price of $245.14, indicating potential for growth. Recent insider trading activity, such as Director Amy W. Schulman selling shares at $148.60, can provide insights into the company's performance and future prospects. Strong institutional investor interest, with major firms like Vanguard Group Inc. and Wellington Management Group LLP increasing their stakes, signaling confidence in the company's long-term potential. Analyst price targets have been revised upwards, with firms like TD Cowen and Citigroup raising their price objectives, suggesting a positive outlook for the stock. Alnylam Pharmaceuticals' current stock price of $153.86 presents a potential buying opportunity for investors looking to enter at a relatively lower price point. Cons Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons: Despite positive analyst ratings, there is always inherent risk in the biopharmaceutical industry due to factors like regulatory challenges, clinical trial outcomes, and competition. Volatility in the stock price of Alnylam Pharmaceuticals, as seen with fluctuations in trading volume and price movements, may pose risks for short-term investors. Market uncertainties, especially in the healthcare sector, can impact the company's performance and stock valuation, leading to unpredictable returns for investors. Dependency on successful drug development pipelines and regulatory approvals for revenue generation, which can be a lengthy and uncertain process in the pharmaceutical industry. Potential macroeconomic factors, such as changes in healthcare policies or global economic conditions, could influence the company's financial performance and stock price. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, June 28, 2024. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com. ALNY Stock Analysis - Frequently Asked Questions Should I buy or sell Alnylam Pharmaceuticals stock right now? 24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 8 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALNY shares. View ALNY analyst ratings or view top-rated stocks. What is Alnylam Pharmaceuticals' stock price target for 2024? 24 equities research analysts have issued 1-year target prices for Alnylam Pharmaceuticals' shares. Their ALNY share price targets range from $150.00 to $400.00. On average, they predict the company's share price to reach $246.41 in the next year. This suggests that the stock has a possible downside of 0.5%. View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts. How have ALNY shares performed in 2024? Alnylam Pharmaceuticals' stock was trading at $191.41 at the beginning of the year. Since then, ALNY stock has increased by 29.4% and is now trading at $247.61. View the best growth stocks for 2024 here. Are investors shorting Alnylam Pharmaceuticals? Alnylam Pharmaceuticals saw a decline in short interest in June. As of June 15th, there was short interest totaling 2,130,000 shares, a decline of 14.1% from the May 31st total of 2,480,000 shares. Based on an average daily volume of 806,100 shares, the days-to-cover ratio is presently 2.6 days. View Alnylam Pharmaceuticals' Short Interest. When is Alnylam Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our ALNY earnings forecast. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its quarterly earnings results on Thursday, May, 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.23. The biopharmaceutical company had revenue of $494.33 million for the quarter, compared to analysts' expectations of $428.01 million. The firm's quarterly revenue was up 54.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.40) EPS. What ETFs hold Alnylam Pharmaceuticals' stock? ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), Morningstar US Small Growth (MSGR), Fidelity Disruptive Medicine ETF (FMED), Tema Cardiovascular and Metabolics ETF (HRTS), Global X Genomics & Biotechnology ETF (GNOM), Horizon Kinetics Medical ETF (MEDX), Principal Healthcare Innovators ETF (BTEC) and First Trust NYSE Arca Biotechnology Index Fund (FBT). What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings? Alnylam Pharmaceuticals issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.7 billion-$1.9 billion, compared to the consensus revenue estimate of $1.9 billion. What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO? 65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD). Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include GAMMA Investing LLC (0.00%). Insiders that own company stock include Akshay Vaishnaw, Amy W Schulman, David E I Pyott, Indrani Lall Franchini, Jeffrey V Poulton, John Maraganore, Kevin Joseph Fitzgerald, Laurie Keating, Michael W Bonney, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALNY) was last updated on 7/3/2024 by MarketBeat.com Staff From Our PartnersRe: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicator...StockEarnings | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredYour bank account could be compromisedPlease read this message carefully … Because your money could be at risk.Weiss Ratings | SponsoredWill Biden Be Replaced?There are growing rumors of a possible Joe Biden replacement following his first debate against Donald Trump. ...Stansberry Research | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
